Stock comparison
Genmab A/S
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 77B | LMAT |
| Benjamin Graham | 64C | 89A | LMAT |
| Philip Fisher | 48D | 81C | LMAT |
| Peter Lynch | 25F | 67B | LMAT |
| Joel Greenblatt | 76B | 56D | GMAB |
| Charlie Munger | 68C | 68D | Tie |
| Terry Smith | 71C | 69D | GMAB |
Side-by-side metrics
| Metric | GMAB | LMAT |
|---|---|---|
| Market cap | $16.5B | $2.23B |
| P/E (TTM) | 6.2x | 37.1x |
| EV/EBIT | 12.0x | 36.6x |
| ROIC (TTM) | 43.78% | 9.43% |
| Gross margin | 93.88% | 72.39% |
| Net margin | 18.23% | 24.35% |
| Revenue CAGR 5y | -18.45% | 12.75% |
| EPS CAGR 5y | -23.48% | 19.04% |
| Debt / Equity | 0.1x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Market cap$16.5Bvs $2.23B+86%
- Debt / Equity0.1xvs 0.5x+84%
- P/E (TTM)6.2xvs 37.1x+83%
- ROIC (TTM)43.78%vs 9.43%+78%
LMAT leads on
- EPS CAGR 5y19.04%vs -23.48%+181%
- Revenue CAGR 5y12.75%vs -18.45%+169%
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 18.23%+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.